Leading pharmaceutical businesses South Korea 2023, by revenue

In 2023, Yuhan Corporation posted the largest revenue among pharmaceutical companies in South Korea, at around 1.86 trillion South Korean won. The company focuses on the production of ingredients for medications as well as finished medications across various medical fields. Other leading companies included Chong Kun Dang and GC Pharma. COVID-19 and Korean pharmaceuticalsThe global coronavirus pandemic affected Korean pharmaceutical companies badly. Most of them suffered from decreased revenues and losses because of poor overseas results from the pandemic, a drop in prescriptions as people avoided hospitals, ongoing legal challenges, and more. A few South Korean pharmaceutical companies enjoyed increased revenues in 2020 and 2021, including Yuhan Corporation. Chong Kun Dang has been developing its own coronavirus (COVID-19) treatment, which won domestic and overseas approval for drug trials in 2021. Meanwhile, GC Pharma is involved in the development of vaccines and treatments for cancer and infectious diseases. Pharmaceutical drugs related to cancer see high usage rates, and development in the field of infectious diseases has naturally surged during the pandemic, helping the company increase their revenue. Pharmaceutical producers in KoreaLeading Korean pharmaceutical producers include Celltrion, Hanmi Pharmaceutical, and Chong Kun Dang. Moderna Korea was the leading company by production value in 2022. Many producers saw increases in sales during the pandemic due to being involved in the production of several medical products related to COVID-19, most notably testing kits, Celltrion's sales revenue increased substantially in 2020 and 2021.

于2023年，尤汉公司成为韩国制药行业收入最高的企业，其收入约为18.6万亿韩元。该公司专注于各类医疗领域药品原料及成药的生产。其他领先企业包括崇康堂和GC制药。在全球冠状病毒大流行期间，韩国制药行业遭受重创。大多数企业因海外业务受疫情负面影响、处方减少（人们避免前往医院）、持续的法律挑战等因素而遭受收入下降和亏损。然而，尤汉公司、崇康堂等少数韩国制药企业在2020年和2021年实现了收入增长。崇康堂一直在研发针对冠状病毒（COVID-19）的治疗方案，并于2021年获得国内外药物临床试验的批准。与此同时，GC制药参与了疫苗及癌症和传染病治疗药物的研发。与癌症相关的药品使用率较高，在疫情爆发期间，传染病领域的研发自然激增，这有助于该公司收入的增长。韩国领先的制药生产商包括Celltrion、韩美制药和崇康堂。Moderna韩国公司于2022年以生产价值领先。许多生产商在疫情期间因参与生产与COVID-19相关的多种医疗产品（尤其是检测盒）而实现销售额增长，其中Celltrion在2020年和2021年的销售额收入大幅增加。